D E Faries

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Simple options for improving signal detection in antidepressant clinical trials
    Craig H Mallinckrodt
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Psychopharmacol Bull 40:101-14. 2007
  2. ncbi request reprint Analysis of treatment effectiveness in longitudinal observational data
    Douglas Faries
    Outcomes Research, Eli Lilly and Company, Indianapolis, Indiana, USA
    J Biopharm Stat 17:809-26. 2007
  3. pmc Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder
    Xianchen Liu
    Former employee, Eli Lilly and Company, Indianapolis, Indiana, USA
    Clinicoecon Outcomes Res 3:63-72. 2011
  4. doi request reprint Evaluating the impact of unmeasured confounding with internal validation data: an example cost evaluation in type 2 diabetes
    Douglas Faries
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Value Health 16:259-66. 2013
  5. pmc Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial
    Douglas Faries
    Eli Lilly and Company, Lilly Corporate Center, DC 5024, Indianapolis, IN 46285, USA
    BMC Med Res Methodol 12:142. 2012
  6. pmc The cost of relapse and the predictors of relapse in the treatment of schizophrenia
    Haya Ascher-Svanum
    US Outcomes Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 10:2. 2010
  7. pmc Cost of antipsychotic polypharmacy in the treatment of schizophrenia
    Baojin Zhu
    Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 8:19. 2008
  8. pmc Predictors of switching antipsychotic medications in the treatment of schizophrenia
    Allen W Nyhuis
    Eli Lilly and Company, Indianapolis, IN USA
    BMC Psychiatry 10:75. 2010
  9. pmc Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 6:8. 2006
  10. pmc Evaluating dose response from flexible dose clinical trials
    Ilya Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis Indiana, USA
    BMC Psychiatry 8:3. 2008

Detail Information

Publications39

  1. ncbi request reprint Simple options for improving signal detection in antidepressant clinical trials
    Craig H Mallinckrodt
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Psychopharmacol Bull 40:101-14. 2007
    ..Researchers may be able to take advantage of these easy-to-implement methods while we wait for further improvements in other areas...
  2. ncbi request reprint Analysis of treatment effectiveness in longitudinal observational data
    Douglas Faries
    Outcomes Research, Eli Lilly and Company, Indianapolis, Indiana, USA
    J Biopharm Stat 17:809-26. 2007
    ..Marginal structural models are a promising approach to estimation of causal treatment effects in such data...
  3. pmc Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder
    Xianchen Liu
    Former employee, Eli Lilly and Company, Indianapolis, Indiana, USA
    Clinicoecon Outcomes Res 3:63-72. 2011
    ....
  4. doi request reprint Evaluating the impact of unmeasured confounding with internal validation data: an example cost evaluation in type 2 diabetes
    Douglas Faries
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Value Health 16:259-66. 2013
    ..Further research to understand the operating characteristics of these methods in a variety of situations, however, remains...
  5. pmc Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial
    Douglas Faries
    Eli Lilly and Company, Lilly Corporate Center, DC 5024, Indianapolis, IN 46285, USA
    BMC Med Res Methodol 12:142. 2012
    ....
  6. pmc The cost of relapse and the predictors of relapse in the treatment of schizophrenia
    Haya Ascher-Svanum
    US Outcomes Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 10:2. 2010
    ..To assess the direct cost of relapse and the predictors of relapse during the treatment of patients with schizophrenia in the United States...
  7. pmc Cost of antipsychotic polypharmacy in the treatment of schizophrenia
    Baojin Zhu
    Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 8:19. 2008
    ..This study compared the costs of antipsychotic polypharmacy for patients who initiated on 1 of the 3 most commonly prescribed atypical antipsychotics - olanzapine, quetiapine, or risperidone...
  8. pmc Predictors of switching antipsychotic medications in the treatment of schizophrenia
    Allen W Nyhuis
    Eli Lilly and Company, Indianapolis, IN USA
    BMC Psychiatry 10:75. 2010
    ..To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia...
  9. pmc Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 6:8. 2006
    ..This naturalistic study compares atypical and typical antipsychotics on time to all-cause medication discontinuation, a recognized index of medication effectiveness in the treatment of schizophrenia...
  10. pmc Evaluating dose response from flexible dose clinical trials
    Ilya Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis Indiana, USA
    BMC Psychiatry 8:3. 2008
    ..The true dose effect in flexible-dose clinical trials may be obscured and even reversed because dose and outcome are related...
  11. pmc Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 9:46. 2009
    ....
  12. pmc Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 10:11. 2010
    ..This study assessed the prevalence of encounters with the criminal justice system, encounter types, and the estimated cost attributable to these encounters in the one-year treatment of persons with schizophrenia...
  13. pmc Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example
    Douglas E Faries
    Lilly USA, LLC, Indianapolis, Indiana, USA
    Cost Eff Resour Alloc 7:11. 2009
    ..Given the importance of quality economic research on the cost of switching treatments, thorough sensitivity analyses should be performed to identify the impact of crisis events around the time of medication change...
  14. ncbi request reprint Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia
    Douglas E Faries
    Eli Lilly and Co, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Curr Med Res Opin 24:1399-405. 2008
    ..Switching medications is common in the treatment of schizophrenia. This study examines the effectiveness of olanzapine therapy following a clinically warranted switch from risperidone during treatment of patients with schizophrenia...
  15. pmc Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
    Douglas E Faries
    US Statistics, Lilly USA, LLC, Indianapolis, IN, USA
    BMC Psychiatry 9:54. 2009
    ..The goal of this research was to assess the clinical and economic ramifications of switching antipsychotics during outpatient management of schizophrenia...
  16. ncbi request reprint The responsiveness of the Hamilton Depression Rating Scale
    D Faries
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Psychiatr Res 34:3-10. 2000
    ..Effect sizes from each individual HAMD item will also be presented to help explain the differences in responsiveness between the scales...
  17. pmc Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
    Douglas Faries
    Outcomes Research, Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 5:26. 2005
    ..This study assessed the annual rate and duration of antipsychotic monotherapy and its inverse, antipsychotic polypharmacy, among schizophrenia patients initiated on commonly used atypical antipsychotic medications...
  18. ncbi request reprint The double-blind variable placebo lead-in period: results from two antidepressant clinical trials
    D E Faries
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Clin Psychopharmacol 21:561-8. 2001
    ..This resulted in an increased drug-placebo treatment difference in one of the two studies but had no effect on the treatment difference in the other study...
  19. ncbi request reprint Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial
    Sandra L Tunis
    US Medical Division, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Value Health 9:77-89. 2006
    ....
  20. doi request reprint Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia
    H Ascher-Svanum
    Lilly Corporate Center, DC 4133, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Eur Psychiatry 26:313-9. 2011
    ..This post-hoc analysis assessed supplementation of olanzapine long-acting injection (olanzapine-LAI) with oral olanzapine...
  21. ncbi request reprint An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia
    Sandra L Tunis
    Health Economics and Outcomes Research, IMS Health, Noblesville, IN, USA
    Curr Med Res Opin 23:97-104. 2007
    ..The objective of this study was to examine the ability of selected variables to predict antipsychotic persistence among patients receiving olanzapine or risperidone as initial treatment...
  22. ncbi request reprint Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study
    David Michelson
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    J Am Acad Child Adolesc Psychiatry 43:896-904. 2004
    ..Attention-deficit/hyperactivity disorder (ADHD) is typically treated over extended periods; however, few placebo-controlled, long-term studies of efficacy have been reported...
  23. doi request reprint Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorder
    Xianchen Liu
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 4123, Indianapolis, IN 46285, USA
    Int Clin Psychopharmacol 25:315-22. 2010
    ..The findings suggest that patients initiated with a dose of 60 mg/day of duloxetine seem to be more adherent to and persistent with the medication than those initiated with less or more than 60 mg/day...
  24. pmc Costs of treating patients with schizophrenia who have illness-related crisis events
    Baojin Zhu
    Eli Lilly and Company, Indianapolis, USA
    BMC Psychiatry 8:72. 2008
    ..This naturalistic prospective study assessed the association of recent crises with mental health treatment costs among persons receiving treatment for schizophrenia...
  25. ncbi request reprint Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care
    Haya Ascher-Svanum
    Eli Lilly and Co, Indianapolis, Ind, USA
    J Clin Psychiatry 67:453-60. 2006
    ....
  26. doi request reprint Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 26:2403-10. 2010
    ..To identify reasons for discontinuation and continuation of antipsychotic medications in the treatment of schizophrenia from the patients' and their clinicians' perspectives...
  27. pmc Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Bull 34:1163-71. 2008
    ..This study assessed the predictive accuracy of early nonresponse to treatment and its clinical, functional, and economic ramifications in the naturalistic treatment of predominately chronic outpatients treated for schizophrenia...
  28. ncbi request reprint Comparing time to onset of response in antidepressant clinical trials using the cure model and the Cramer-von Mises test
    R N Tamura
    Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Stat Med 19:2169-84. 2000
    ..Results of the simulation study suggest that for common designs and sample sizes used in such trials, the statistic has reasonable size and power properties as long as censoring is moderate...
  29. ncbi request reprint ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument
    S Zhang
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Int J Methods Psychiatr Res 14:186-201. 2005
    ..Overall, the data from this study support the use of the ADHD RS as a clinician-rated instrument for assessing the severity of ADHD symptoms in children and adolescents in Europe...
  30. ncbi request reprint Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine
    Amy R Perwien
    Outcomes Research, US Medical Division, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Dev Behav Pediatr 25:264-71. 2004
    ..Findings demonstrate the positive impact of atomoxetine on HRQL in children with ADHD...
  31. ncbi request reprint Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes?
    Amy R Perwien
    Outcomes Research, US Medical Division, Eli Lilly and Company, Indianapolis, Indiana, USA
    J Child Adolesc Psychopharmacol 16:713-24. 2006
    ..This study examines the long-term effects of pharmacological treatment with atomoxetine on HRQL in children and adolescents with ADHD...
  32. ncbi request reprint Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder
    Joseph Biederman
    Massachusetts General Hospital, Boston, Massachusetts, USA
    Pediatrics 110:e75. 2002
    ..Atomoxetine is a potent inhibitor of the presynaptic norepinephrine transporter with minimal affinity for other noradrenergic receptors or for other neurotransmitter transporters or receptors...
  33. ncbi request reprint Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder
    Thomas Spencer
    Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 63:1140-7. 2002
    ..Results of 2 proof-of-concept studies are reported that tested the hypothesis that a selective inhibitor of presynaptic norepinephrine uptake would be effective for the treatment of ADHD in school-aged children...
  34. ncbi request reprint Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use
    David A Smelson
    J Clin Psychopharmacol 26:666-7. 2006
  35. ncbi request reprint A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year
    Jan K Buitelaar
    University Medical Center St Radboud, Nijmegen, The Netherlands
    Biol Psychiatry 61:694-9. 2007
    ..The efficacy of atomoxetine in maintaining symptom response following 1 year of treatment was assessed in children and adolescents (n = 163) with DSM-IV defined attention-deficit/hyperactivity disorder (ADHD)...
  36. ncbi request reprint Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning
    Ronald T Brown
    Temple University, Department of Public Health, PA 19140, USA
    Clin Pediatr (Phila) 45:819-27. 2006
    ..The effects of atomoxetine on other functional outcomes including academic performance and health-related outcomes are of interest, albeit less compelling for this particular investigation, than for the effects on overt symptom display...
  37. pmc The burden of depressive symptoms in the long-term treatment of patients with schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland at Baltimore, School of Medicine, USA
    Schizophr Res 90:186-97. 2007
    ..To prospectively measure the link between depressive symptoms and functional outcomes in the long-term treatment of people with schizophrenia...
  38. ncbi request reprint Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL)
    Louis S Matza
    Center for Health Outcomes Research at UBC, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
    Qual Life Res 16:1511-20. 2007
    ....
  39. doi request reprint Abuse liability assessment of atomoxetine in a drug-abusing population
    Donald R Jasinski
    Johns Hopkins School of Medicine, Center for Chemical Dependence, 4940 Eastern Avenue, Baltimore, MD 21224, USA
    Drug Alcohol Depend 95:140-6. 2008
    ..This study assessed the abuse potential of atomoxetine in stimulant-preferring drug abusers compared to methylphenidate and phentermine as positive controls and desipramine and placebo as negative controls...